$316.89
3.17% yesterday
NYSE, Nov 13, 10:00 pm CET

Bio-Rad Laboratories Inc. - Ordinary Shares - Class A Stock price

$316.89
+13.18 4.34% 1M
+63.74 25.18% 6M
-11.62 3.54% YTD
-46.31 12.75% 1Y
-105.21 24.93% 3Y
-285.47 47.39% 5Y
+180.85 132.94% 10Y
+257.51 433.66% 20Y
NYSE, Closing price Thu, Nov 13 2025
-10.39 3.17%

Key metrics

Basic
Market capitalization
$8.6b
Enterprise Value
$8.3b
Net debt
positive
Cash
$1.4b
Shares outstanding
27.0m
Valuation (TTM | estimate)
P/E
negative | 32.3
P/S
3.3 | 3.4
EV/Sales
3.3 | 3.3
EV/FCF
24.8
P/B
1.3
Financial Health
Equity Ratio
70.2%
Return on Equity
-28.1%
ROCE
2.9%
ROIC
2.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$2.6b | $2.6b
EBITDA
- | $456.0m
EBIT
$262.5m | $307.5m
Net Income
$-675.9m | $273.6m
Free Cash Flow
$336.7m
Growth (TTM | estimate)
Revenue
-0.9% | 1.9%
EBITDA
- | 51.1%
EBIT
-23.5% | 3.0%
Net Income
13.2% | 114.8%
Free Cash Flow
50.5%
Margin (TTM | estimate)
Gross
52.4%
EBITDA
- | 17.4%
EBIT
10.3%
Net
-26.4% | 10.5%
Free Cash Flow
13.2%
More
EPS
$-25.1
FCF per Share
$12.5
Short interest
4.9%
Employees
8k
Rev per Employee
$330.0k
Show more

Is Bio-Rad Laboratories Inc. - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Bio-Rad Laboratories Inc. - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Bio-Rad Laboratories Inc. - Ordinary Shares - Class A forecast:

6x Buy
60%
4x Hold
40%

Analyst Opinions

10 Analysts have issued a Bio-Rad Laboratories Inc. - Ordinary Shares - Class A forecast:

Buy
60%
Hold
40%

Financial data from Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,557 2,557
1% 1%
100%
- Direct Costs 1,217 1,217
3% 3%
48%
1,341 1,341
5% 5%
52%
- Selling and Administrative Expenses 807 807
1% 1%
32%
- Research and Development Expense 271 271
9% 9%
11%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 263 263
23% 23%
10%
Net Profit -676 -676
13% 13%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Rad Laboratories Inc. - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Head office United States
CEO Norman Schwartz
Employees 7,700
Founded 1952
Website www.bio-rad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today